drugset / Trial / NCT03097029
Use of Pancreatic Enzymes in Short Bowel Syndrome
NaSingle-groupOpen-labelTreatment
Summary
Patients with short bowel syndrome have a high mortality rate that is mainly attributed to complications from central lines and long-term intravenous (IV) nutrition. There are few medical therapies to date that improve gut absorption in patients with short bowel syndrome. The primary objective of this study is to evaluate if absorption from the GI tract improves in subjects with short bowel syndrome following therapy with pancreatic enzymes.
Timeline
- Start
- 2017-03-24
- Primary completion
- 2019-02-01
- Completion
- 2019-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pancrelipase | Protein / enzyme biologic | — | — |